TARSUS PHARMACEUTICALS, INC.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$562M
↑+49.1% +$185Mvs FY2024
Total Liabilities
$219M
↑+43.5% +$66Mvs FY2024
Equity
$343M
↑+53.0% +$119Mvs FY2024
Cash
$184M
↑+93.7% +$89Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $562M | $377M |
| Current Assets | $523M | $357M |
| Cash | $184M | $95M |
| ST Investments | $234M | $197M |
| Receivables | $85M | $47M |
| Inventory | $4M | $3M |
| Other Current | $16M | $16M |
| Non-Current Assets | $39M | $20M |
| PPE | $12M | $2M |
| Goodwill | $0 | $0 |
| Intangibles | $7M | $8M |
| Investments | $4M | $3M |
| Other Non-Current | $16M | $7M |
| Total Liab+Eq | $562M | $377M |
| Current Liab. | $136M | $81M |
| Accounts Payable | $16M | $9M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $119M | $71M |
| Non-Current Liab. | $83M | $72M |
| Long-Term Debt | $72M | $72M |
| Other LT Liab. | $11M | $0 |
| Equity | $343M | $225M |
| Retained Earnings | $427M | $360M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · TARS · Comparing FY2025 vs FY2024